Alexion has agreed to pay up to $1.2bn for Syntimmune and its lead asset SNT001, a monoclonal antibody designed to treat warm autoimmune haemolytic anaemia.
Think of big biotech hubs in the US and two areas will immediately come to mind: Boston, on the east coast, and San Francisco, on the west – Los Angeles wants to change that.
BioPharma-Reporter (BPR) discusses with Jennifer Fox (JF), co-chair of Brinks Gilson & Lione’s biopharma practice group, the provisional detail revealed from the US administration’s proposed trade deal with Mexico, and its potential impact on the...
A fortuitous finding in preclinical research, whereby mice injected with a modified protein developed hair, has prompted Follicum AB’s research and development into the alopecia space.
BioProcess International has kicked off at Biotech Week Boston. BioPharma-Reporter is here to cover the best of the sessions and the reactions from everyone present.
On the eve of Boston Biotech Week, a report was released by MassBio that claimed 48% of all biotech investment in 2017 was accounted for by Massachusetts-based companies.
It has been revealed that the EMA is awarding significantly fewer contracts to evaluate the application of new drugs to the MHRA, as the Brexit deadline nears.
The Testa BioProcess Innovation Center in Sweden will help academics, startups, and biopharmaceutical companies secure industrial proof-of-concepts quicker, and with less cost, says GE Healthcare.
Biotech M&A started off a bang this year and as the first half of the year has drawn to a close, biotech IPOs have reached a number that could see 2018 become a record-breaker.
The National Institute of Allergy and Infectious Diseases is enrolling volunteers for a first-in-human experimental treatment trial for its mAb to treat the Ebola virus.
Rubius has announced plans to acquire Alexion’s manufacturing facility in Rhode Island, where the latter made immunosuppressant Soliris before exiting the site last year.
Researchers from MIT have devised a way for T cells to be engineered to carry nanoparticle ‘backpacks’ that can deliver the payload only when interacting with the target tumour cells.
Sanofi will support development of polypeptides, gene therapy, monoclonal antibodies and multi-specific antibodies through the expansion of its R&D plant in Chengdu, Sichuan province, China.
Eisai says it is creating a research facility for ‘genetics-guided dementia discovery’ in the US and joining a Japanese industry-academia-government collaboration aimed at developing nucleic acid-based drugs.
Microbiome start-up will receive up to €454 million in upfront and milestone payments
UK-based Microbiotica will collaborate with Roche-owned biotechnology group Genentech in the hunt for new microbiome-based therapeutics and biomarkers for its inflammatory bowel disease (IBD) pipeline.
AveXis – a Novartis company – has added a manufacturing facility in North Carolina to its site network, where it will make investigational therapies for neurological genetic diseases.
In a move aimed to bolster its immuno-oncology program, Eli Lilly and Company has acquired Armo BioSciences for $50 per share, or approximately $1.6bn.
KBI will provide services to ReForm to further develop and validate its biologic formulation platform and in turn, will gain access to ReForm’s proprietary excipient technologies.
“We need Big Pharma and we are getting Big Pharma,” says Dyadic
Dyadic International says a string of deals shows biopharma is beginning to embrace its low-cost and high-yielding – yet commercially unproven – fungus-based expression platform.
The traditionally small molecule firm was ‘late to the biologics game’, but Sanofi says a mixture of external partnerships and mergers are helping shift focus.
Egg adaptation is the biggest culprit in this year’s poor flu vaccine efficacy says Novavax, a firm developing a product based on recombinant protein nanoparticles.
A warning letter at manufacturing partner Celltrion could delay approvals of the potential migraine prevention monoclonal antibody fremanezumab and two biosimilar candidates, says Teva.
GigaGen has relocated laboratory and office space in San Francisco to boost development of antibody therapeutics for patients with immune dysregulation.
